Pill Identifier App

Telik Announces Preclinical Presentations at AACR Annual Meeting

PALO ALTO, Calif., April 07, 2008, 2008 /PRNewswire-FirstCall/ -- Telik, Inc. announced that four abstracts highlighting results from its Research and Development programs will be presented at the 99th annual meeting of the American Association for Cancer Research (AACR) in San Diego.

    Details of the presentations are as follows:


    -- Identification and Characterization of Novel Tyrosine Kinase Inhibitors

       Targeting Vascular Endothelial Growth Factor Receptor 2; Sunday, April

        13, 2008, 1:00 - 5:00pm; Experimental and Molecular Therapeutics 10;

       Abstract # 1439


    -- Mechanism of Induction of Apoptosis by TLK199 (Telintra(R)) in Human

       Leukemia Cell Lines; Monday, April 14, 2008, 8:00am - 12noon;

       Experimental and Molecular Therapeutics 10; Abstract # 2270


    -- Identification of a Novel Class of Nonpeptidyl Small-Molecule

       Inhibitors of    the Human Proteasome; Monday, April 14, 2008,

       1:00 - 5:00pm; Experimental and Molecular Therapeutics 28;

       Abstract # 3271


    -- Target-Related Affinity Profiling (TRAP(R)):  Efficient Cancer Drug

       Discovery at Telik; Tuesday, April 15, 2008; 1:00 - 5:00pm; Cancer

       Chemistry 11; Abstract # 4754


Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates.

TELIK, the Telik logo, TELCYTA, TELINTRA and TRAP are trademarks or registered trademarks of Telik, Inc.

CONTACT: Patricia P. Frias, Corporate Communications of Telik, Inc.,+1-650-845-7927, pfrias@telik.com

Web site: http://www.telik.com/

Ticker Symbol: (NASDAQ-NMS:TELK)

Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: April 2008

View comments

Hide
(web2)